OncoMatch/Clinical Trials/NCT06328686
Arginine and Whole Brain Radiation Therapy for the Treatment of Patients With Brain Metastases
Is NCT06328686 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies non-drug interventions for metastatic malignant neoplasm in the brain.
This early phase I trial evaluates different administration techniques (oral or intravenous) for arginine and tests the safety of giving arginine with whole brain radiation therapy in patients who have cancer that has spread from where it first started (primary site) to the brain (brain metastases). Arginine is an essential amino acid. Amino acids are the molecules that join together to form proteins in the body. Arginine supplementation has been shown to improve how brain metastases respond to radiation therapy. The optimal dosing of arginine for this purpose has not been determined. This study measures the level of arginine in the blood with oral and intravenous dosing at specific time intervals before and after drug administration to determine the best dosing strategy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Disease stage
Metastatic disease required
Lab requirements
Kidney function
creatinine ≤ 1.5 x the upper limit of normal
Liver function
ALT ≤ 6x the upper limit of normal
Creatinine > 1.5 x the upper limit of normal; Alanine aminotransferase (ALT) > 6x the upper limit of normal
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Emory University Hospital/Winship Cancer Institute · Atlanta, Georgia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify